Showing 141-150 of 154 results for "".
- Phase 3 Data Show Promius Pharma's DFD-01 Met Primary Endpoints for the Treatment of Moderate Psoriasishttps://practicaldermatology.com/news/phase-3-data-show-promius-pharmas-dfd-01-met-primary-endpoints-for-the-treatment-of-moderate-psoriasis/2458833/Findings from two Phase III studies for Promius Pharma’s investigational psoriasis drug DFD-01 show that the agent achieved the primary endpoint at day 15. The primary endpoint was the proportion of patients achieving treatment success at day 15 for both studies. In addition, both studies met a sec…
- A Novel Dual-Wavelength, Nd:YAG, Picosecond-domain Laser Safely and Effectively Removes Multicolor Tattooshttps://practicaldermatology.com/news/a-novel-dual-wavelength-ndyag-picosecond-domain-laser-safely-and-effectively-removes-multicolor-tattoos/2458848/Research conducted by Eric F. Bernstein MD, MSc; Kevin T. Schomacker PhD; Lisa D. Basilavecchio RN; Jessica M. Plugis; and Jayant D. Bhawalkar PhD, published in the September 2015 issue of Lasers in Surgery and Medicine (LSM), evaluated 21 tattooed subjects between the ages of 19-55 who had a total…
- ASDS Finds Age Affects Facial Treatment Preferenceshttps://practicaldermatology.com/news/asds-finds-age-affects-facial-treatment-preferences/2458908/A research-based analysis published in Dermatologic Surgery found that facial treatment preferences among women often are tied to their age. Younger women are more likely to seek cosmetic medical treatments for the upper face while women 50 and older prioritize treatments of the lower face, accordi…
- Envy Medical Appoints Chief Marketing Officer to Executive Teamhttps://practicaldermatology.com/news/envy-medical-appoints-chief-marketing-officer-to-executive-team/2459002/Envy Medical Products, Inc., appointed Shauna Lahiri to the newly created role of Chief Marketing Officer. Ms. Lahiri brings a 17-year record of building successful global marketing strategies, building and launching new brands achieving leadership in mass, consumer and niche categories. She will b…
- Syneron Candela Expands Capabilities of UltraShape Platform, Receives FDA Clearance for the New U-Sculpt Transducer and Enhanced Ultrasound Powerhttps://practicaldermatology.com/news/20141117-syneron_candela_expands_capabilities_of_ultrashape_platform_receives_fda_clearance_for_the_new_u-sculpt_transducer_and_enhanced_ultrasound_power/2459064/The FDA cleared Syneron Medical Ltd.'s U-Sculpt transducer for the UltraShape non-invasive fat destruction platform. The FDA also cleared the V3.1 platform for a 25 percent increase in Ultrasound power in the new U-sculpt transducer and the previously cleared larger VDF transducer. This 25 percent …
- Medimetriks Pharmaceuticals Announces New Members Elected to Board of Directorshttps://practicaldermatology.com/news/20140923-medimetriks_pharmaceuticals_announces_new_members_elected_to_board_of_directors/2459108/Andrew Lary and William Resnick have been elected as independent directors of the Board of Directors of Medimetriks Pharmaceuticals, which develops, licenses, and commercializes prescription skincare products with a focus on dermatology and select specialty markets. Mr. Lary, who will serve on M…
- Steroids Found to be Widely Prescribed by Dermatologists for Psoriasis Managementhttps://practicaldermatology.com/news/20140220-steroids_found_to_be_widely_prescribed_by_dermatologists_for_psoriasis_management/2459337/When it comes to psoriasis management guidelines, use of systemic corticosteroids are discouraged, but according to a new study from Wake Forest Baptist Medical Center, they are widely prescribed by dermatologists. Researchers at The Center for Dermatology Research at Wake Forest Baptist assessed h…
- Scioderm Initiates Phase IIB Study of SD-101 to Treat Epidermolysis Bullosahttps://practicaldermatology.com/news/20140107-scioderm_initiates_phase_iib_study_of_sd-101_to_treat_epidermolysis_bullosa/2459377/A Phase IIB study to evaluate the efficacy and safety of SD-101, a novel topical therapy, for the treatment of non-healing wounds in patients with Epidermolysis Bullosa (EB), was initiated, according to Scioderm, Inc. The Phase IIB study (SD-003) is a multi-site, prospective…
- Caliber Imaging & Diagnostics Appoints Robert P. Fischmann VP of Operationshttps://practicaldermatology.com/news/20131125-caliber_imaging__diagnostics_appoints_robert_p_fischmann_vp_of_operations/2459406/Caliber Imaging & Diagnostics, formerly Lucid, Inc., has appointed Robert P. Fischmann to the role of Vice President of Operations, a newly created position. Mr. Fischmann's responsibilities at Caliber I.D. will include managing all of the Company's production control, production process developme…
- Research Shows CLn BodyWash Effective for Children with Eczemahttps://practicaldermatology.com/news/20130603-research_shows_cln_bodywash_effective_for_children_with_eczema/2459524/Clinical study results show that TopMD Skin Care's CLn BodyWash helps ease the symptoms of eczema. The article, “A Novel Sodium Hypochlorite Cleanser Shows Clinical Response and Excellent Acceptability in the Treatment of Atopic Dermatitis,” details the results of 18 children ages 2 to 11 with mode…